STE STERIS plc
Orthopedic, Prosthetic & Surgical Appliances & Supplies · NYSE · SEC CIK 1757898 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY8.1%
TTM net income YoY20.1%
TTM EPS YoY21.7%
Revenue 3-yr CAGR8.6%
Net income 3-yr CAGR14.6%
Margins
Gross margin44.6%
Operating margin19.0%
Net margin13.4%
FCF margin15.2%
EBITDA margin27.0%
Returns
ROE11.6%
ROA7.8%
ROIC (approx.)10.0%
Asset turnover0.58x
Leverage & solvency
Liabilities / assets32.1%
Debt / equity0.26x
Current ratio2.05x
Interest coverage20.53x
Cash quality & payout
Operating cash flow / net income1.56x
Accruals ratio-4.4%
Payout ratio30.5%
Capex / revenue5.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q22026-09-30 | 2027Q12026-06-30 | 2026Q4*2026-03-31 | 2026Q32025-12-31 | 2026Q22025-09-30 | 2026Q12025-06-30 | 2025Q4*2025-03-31 | 2025Q32024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.59B | $1.49B | $1.59B | $1.50B | $1.46B | $1.39B | $1.48B | $1.37B |
| Cost of revenue | $877.80M | $808.60M | $891.20M | $840.70M | $814.40M | $763.10M | $839.40M | $760.20M |
| Gross profit | $710.80M | $684.20M | $697.10M | $655.50M | $645.90M | $628.00M | $641.20M | $610.30M |
| R&D expense | $31.50M | $28.60M | $28.80M | $29.50M | $28.20M | $26.40M | $27.60M | $27.40M |
| SG&A expense | $366.00M | $369.70M | $351.80M | $352.30M | $349.70M | $353.80M | $333.90M | $335.50M |
| Operating income | $294.30M | $285.80M | $316.80M | $273.20M | $265.80M | $246.00M | $216.10M | $245.30M |
| Interest expense | $11.20M | $15.80M | $15.10M | $14.90M | $14.90M | $15.90M | $17.20M | $19.10M |
| Pretax income | $288.00M | $273.50M | $304.50M | $257.80M | $253.10M | $231.90M | $197.30M | $228.70M |
| Income tax | $73.90M | $72.50M | $84.20M | $63.50M | $60.60M | $53.90M | $50.45M | $55.40M |
| Net income | $213.70M | $200.10M | $220.20M | $192.90M | $191.90M | $177.40M | $145.60M | $173.50M |
| EBITDA | $419.90M | $409.60M | $440.20M | $395.20M | $387.50M | $365.40M | $338.40M | $371.20M |
| EPS (basic) | — | — | — | 1.96 | 1.95 | 1.80 | — | 1.76 |
| EPS (diluted) | — | — | — | 1.96 | 1.94 | 1.79 | — | 1.75 |
| Dividends declared per share | 0.69 | 0.63 | 0.63 | 0.63 | 0.63 | 0.57 | 0.57 | 0.57 |
| Weighted avg. shares (diluted) | 97.60M | 97.90M | — | 98.60M | 98.80M | 98.80M | — | 98.90M |
| Balance sheet | ||||||||
| Cash & equivalents | $531.10M | $482.30M | $439.60M | $423.70M | $319.20M | $279.70M | $171.70M | $155.20M |
| Receivables | $1.01B | $1.01B | $1.09B | $990.60M | $947.30M | $947.10M | $1.04B | $915.20M |
| Inventory | $737.00M | $712.10M | $631.80M | $673.50M | $658.50M | $641.20M | $581.30M | $649.56M |
| Current assets | $2.48B | $2.45B | $2.39B | $2.29B | $2.11B | $2.06B | $2.00B | $1.90B |
| PP&E, net | $2.19B | $2.17B | $2.16B | $2.13B | $2.09B | $2.05B | $1.96B | $1.92B |
| Goodwill | $4.18B | $4.19B | $4.19B | $4.23B | $4.22B | $4.22B | $4.10B | $4.04B |
| Intangibles | $1.50B | $1.56B | $1.62B | $1.69B | $1.75B | $1.82B | $1.85B | $1.92B |
| Total assets | $10.71B | $10.74B | $10.74B | $10.59B | $10.41B | $10.40B | $10.15B | $10.01B |
| Current liabilities | $1.21B | $1.28B | $1.15B | $922.30M | $888.90M | $926.60M | $1.02B | $891.12M |
| Short-term debt | $243.10M | $243.40M | $118.90M | $0 | $0 | $0 | $125.00M | $125.00M |
| Long-term debt | $1.65B | $1.65B | $1.81B | $1.90B | $1.90B | $1.90B | $1.92B | $2.04B |
| Total debt | $1.89B | $1.89B | $1.93B | $1.90B | $1.90B | $1.90B | $2.04B | $2.16B |
| Total liabilities | $3.44B | $3.51B | $3.54B | $3.42B | $3.39B | $3.44B | $3.53B | $3.58B |
| Shareholders' equity | $7.26B | $7.21B | $7.18B | $7.15B | $7.01B | $6.96B | $6.60B | $6.42B |
| Net debt | $1.36B | $1.41B | $1.49B | $1.47B | $1.58B | $1.62B | $1.87B | $2.01B |
| Shares outstanding | 97.10M | 97.50M | 97.80M | 98.10M | 98.10M | 98.50M | 98.30M | 98.25M |
| Cash flow statement | ||||||||
| Operating cash flow | $289.00M | $367.10M | $335.40M | $298.20M | $287.80M | $420.00M | $260.80M | $332.80M |
| Capital expenditure | $76.10M | $87.50M | $90.20M | $98.70M | $86.50M | $93.60M | $70.90M | $89.20M |
| Free cash flow | $212.90M | $279.60M | $245.20M | $199.50M | $201.30M | $326.40M | $189.90M | $243.60M |
| Investing cash flow | -$76.10M | -$108.50M | -$217.20M | -$98.50M | -$88.30M | -$108.50M | -$69.80M | -$123.90M |
| Financing cash flow | -$163.50M | -$213.50M | -$97.90M | -$98.00M | -$159.20M | -$213.10M | -$178.10M | -$214.40M |
| Depreciation & amortization | $125.60M | $123.80M | $123.40M | $122.00M | $121.70M | $119.40M | $122.30M | $125.90M |
| Stock-based compensation | $21.70M | $12.80M | $12.90M | $15.70M | $21.20M | $11.90M | $9.80M | $15.30M |
| Dividends paid | $67.00M | $61.40M | $61.80M | $61.90M | $61.90M | $56.20M | $56.00M | $56.20M |
| Share buybacks | $100.40M | $115.50M | $74.30M | $50.10M | $100.50M | $10.60M | $200,000 | $100.50M |
Free plan shows the latest 8 periods; Pro shows all 38 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.